Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX

Autor: FA Baglia, D Sinha, PN Walsh

Publikováno v: Blood. 74:244-251

To probe the molecular interactions of factor XI we have prepared two monoclonal antibodies (MoAbs; 5F7 and 3C1), each of which binds the heavy chain of reduced and alkylated factor XIa. Competitive solid phase radioimmunoassay (RIA) binding studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52a1998ff84c23880aff6d6256c6afec
https://doi.org/10.1182/blood.v74.1.244.bloodjournal741244

Factor XI antigen and activity in human platelets

Autor: GP Tuszynski, SJ Bevacqua, AH Schmaier, RW Colman, PN Walsh

Publikováno v: Blood. 59(6)

Washed platelets, contaminated with less than 0.20% plasma factor XI, were examined for the presence of factor XI antigen and activity. These platelets contained a factor-XI-like coagulant activity (0.67 +/- 0.11 U/10(11) platelets) that remained con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38eefbb781df06257d11921c4c2b7b5
https://pubmed.ncbi.nlm.nih.gov/7044446

Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells.

Autor: Slichter CK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Friedrich DP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Smith RJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Walsh PN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Mize G; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Czartoski JL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Department of Global Health, University of Washington, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States; Department of Laboratory Medicine, University of Washington, Seattle, WA, United States., Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Department of Global Health, University of Washington, Seattle, WA, United States. Electronic address: nfrahm@fhcrc.org.

Publikováno v: Journal of immunological methods [J Immunol Methods] 2014 Feb; Vol. 404, pp. 71-80. Date of Electronic Publication: 2013 Dec 25.

P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.

Autor: Navaneetham D; The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA., Wu W, Li H, Sinha D, Tuma RF, Walsh PN

Publikováno v: Journal of biochemistry [J Biochem] 2013 Feb; Vol. 153 (2), pp. 221-31. Date of Electronic Publication: 2012 Nov 20.

Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.

Autor: Marcinkiewicz MM; Sol Sherry Thrombosis Research Center, University School of Medicine, Philadelphia, Pennsylvania 19140, USA., Sinha D, Walsh PN

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2012 Feb 24; Vol. 287 (9), pp. 6187-95. Date of Electronic Publication: 2011 Dec 29.